<div id="readability-page-1"><p>Aberdeen Group plc cut its holdings in  Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 54.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 264,869 shares of the company's stock after selling 322,000 shares during the period. Aberdeen Group plc owned 0.44% of Structure Therapeutics worth $18,422,000 as of its most recent filing with the SEC.</p><div><p><span></span><span>Get <strong>Structure Therapeutics</strong> alerts:</span></p></div><ul><li>3 Companies at the Forefront of the GLP-1 Pill Wars</li></ul><p>A number of other institutional investors have also made changes to their positions in GPCR. E. Ohman J or Asset Management AB bought a new position in  Structure Therapeutics during the fourth quarter valued at about $314,000.  Gilbert &amp; Cook Inc. acquired a new stake in shares of  Structure Therapeutics during the 4th quarter worth approximately $395,000.  JPMorgan Chase &amp; Co. grew its holdings in shares of  Structure Therapeutics by 37.0% during the 3rd quarter. JPMorgan Chase &amp; Co. now owns 58,148 shares of the company's stock worth $1,628,000 after purchasing an additional 15,706 shares in the last quarter.  Alyeska Investment Group L.P. acquired a new stake in shares of  Structure Therapeutics during the 3rd quarter worth approximately $6,856,000.  Finally, Paradigm Biocapital Advisors LP acquired a new stake in shares of  Structure Therapeutics during the 3rd quarter worth approximately $10,440,000. 91.78% of the stock is currently owned by institutional investors. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have recently weighed in on GPCR shares. Jefferies Financial Group  set a $125.00 price objective on Structure Therapeutics and gave the stock a &#34;buy&#34; rating in a report on Thursday, December 11th. JPMorgan Chase &amp; Co. lifted their price objective on Structure Therapeutics from $65.00 to $105.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, January 22nd. Leerink Partners  reissued an &#34;outperform&#34; rating on shares of Structure Therapeutics in a report on Monday, March 16th. William Blair  reiterated an &#34;outperform&#34; rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Finally, Wall Street Zen lowered Structure Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, March 28th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating, one  has given a Hold rating and two have assigned  a Sell rating to the stock. According to MarketBeat, Structure Therapeutics  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $110.00.</p><ul><li>Can Roche Challenge Lilly and Novo in the Weight Loss Market?</li></ul><p><b>View Our Latest Analysis on GPCR</b></p><h2>Structure Therapeutics Trading Down 3.2%</h2><p>GPCR stock opened at $51.77 on Tuesday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $94.90. The firm has a market cap of $3.67 billion, a P/E ratio of -65.53 and a beta of -1.17. The business's 50 day moving average is $63.91 and its 200-day moving average is $53.03. </p><ul><li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li></ul><p>Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14).  Sell-side analysts forecast that  Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year. </p><h2>Structure Therapeutics Profile</h2> (Free Report)<p>Structure Therapeutics <span>NASDAQ: GPCR<span></span></span> is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders. </p><p>The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Structure Therapeutics</li></ul><p><strong>Want to see what other hedge funds are holding GPCR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R1BDUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Structure Therapeutics Right Now?</h2><p>Before you consider Structure Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.</p><p>While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ARKG

<p>Aberdeen Group plc reduced its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ: GPCR) by 54.9%, selling 322,000 shares during the fourth quarter, leaving it with 264,869 shares valued at $18.4 million. Other institutional investors also adjusted their positions in GPCR. Analysts have mixed ratings on the stock, with a consensus price target of $110.00. GPCR shares opened at $51.77, down 3.2%, with a market cap of $3.67 billion. The company focuses on developing therapies targeting G protein-coupled receptors.</p>

Market Beat

Ark Genomic Revolution ETF

iShares Global Healthcare

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Structure Therapeutics

VG Health

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

iShares US Pharma

Aberdeen Group plc Sells 322,000 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR